【摘要】 目的:评估现实治疗环境中贝伐珠单抗与化疗联合治疗转移性结直肠癌(mCRC)的疗效和毒性。方法:收集2010年10月至2013年4月间接受贝伐珠单抗联合化疗治疗的mCRC患者资料,近期疗效评估采用实体瘤疗效评价标准1.1版;Kaplan-Meier法估计生存时间;毒性评估采用国立癌症研究所不良事件标准3.0版。结果:74例患者入组,男性40例,女性34例;年龄31~74岁,中位年龄55.5岁;结肠癌44例,直肠癌30例;一线和二线治疗各37例;63例患者有可测量病灶,一线、二线治疗的客观有效率(ORR)分别为62.8%、28.6%;一线、二线治疗患者的中位无进展生存时间(PFS)和中位总生存时间(OS)分别为8.7个月、4.4个月和25.3个月、14.6个月;奥沙利铂及伊立替康为基础的化疗方案的中位PFS、中位OS分别为8.1个月、5.8个月和21.9个月、17.1个月,组间无统计学差异(P值分别为0.592和0.506)。全组各级高血压的发生率为9.5%、蛋白尿8.1%、静脉血栓形成2.7%、胃肠穿孔2.7%,伤口愈合综合症4.1%,出血17.6%。结论:贝伐珠单抗联合化疗治疗mCRC有效,贝伐珠单抗相关毒性的总体发生率较低。更多还原

【Abstract】 AIM:After approval of bevacizumab in Chinese,post-marketing surveillance studies reported on efficacy and safety was rare.We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients in daily practice.METHODS:All unresectable metastatic colorectal cancer patients who began receiving bevacizumab in participating facilities from October 2010 to April 2013 were retrospectively analyzed for efficacy and safety.Response Evaluation in Solid Tumors criteria,version 1.1,was used for the tumor response rate.The Kaplan-Meier method was used to determine PFS and OS.Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events.RESULTS:A totalof 74 patients were assessed.Response rates were 62.8%,28.6%overall among patients re-ceiving bevacizumab as first-,second-line therapy.Median progression-free survival was 8.7,4.4 months,and median overall survival was25.3,14.6months,respectively.All grade adverse events related to bevacizumab included hypertension in 9.5%, proteinuria in 8.1%,thrombosis in 2.7%,gastrointestinal perforation in 2.7%,poor wound healing in 4.1%and bleeding in 17.6%.CONCLUSION:Althoughthe sample size was small and there were several study limitations,these results suggest that colorectal cancer patients in our center benefit from bevacizumab in combination with chemotherapy and might safely in daily practice.更多还原